KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Work In Process (2016 - 2025)

Astrazeneca (AZN) has 3 years of Work In Process data on record, last reported at $2.8 billion in Q4 2025.

  • For Q4 2025, Work In Process rose 21.69% year-over-year to $2.8 billion; the TTM value through Dec 2025 reached $2.8 billion, up 21.69%, while the annual FY2025 figure was $2.8 billion, 21.69% up from the prior year.
  • Work In Process reached $2.8 billion in Q4 2025 per AZN's latest filing, up from $2.3 billion in the prior quarter.
  • Across five years, Work In Process topped out at $2.8 billion in Q4 2025 and bottomed at $2.3 billion in Q4 2024.
  • Average Work In Process over 3 years is $2.5 billion, with a median of $2.3 billion recorded in 2023.
  • Peak YoY movement for Work In Process: dropped 1.85% in 2024, then rose 21.69% in 2025.
  • A 3-year view of Work In Process shows it stood at $2.3 billion in 2023, then decreased by 1.85% to $2.3 billion in 2024, then increased by 21.69% to $2.8 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Work In Process were $2.8 billion in Q4 2025, $2.3 billion in Q4 2024, and $2.3 billion in Q4 2023.